Arvinas (NASDAQ:ARVN) reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a corporate update.

As quoted in the press release:

“2019 was an exciting year for Arvinas, marked by tremendous clinical and corporate progress. We were delighted to present the first human clinical data from targeted protein degraders along with preclinical data demonstrating the brain-penetrating potential of our PROTAC® protein degraders. These data underscore the potential of our platform to create safe and well-tolerated drugs for the treatment of a variety of life-threatening diseases,” said John Houston, Ph.D., Chief Executive Officer of Arvinas.

Click here to read the full press release.